Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Wyeth Plans to Apply for Prevenar in Japan in 2007
November 27, 2006
- Dainippon Sumitomo Preparing Plan for Overseas Business Expansion
November 20, 2006
- Taisho: Sales of OTC, Ethical Drugs Down in 1st Half
November 20, 2006
- Shionogi: Sluggish Sales of Antibiotics Hurt 1st-Half Results
November 20, 2006
- Tanabe Seiyaku to Announce Generic Business Plan by Next March
November 20, 2006
- Ono: Generic Competition Impacts Sales of Major Products
November 20, 2006
- Midterm Plan to Focus on Improving Profit Structure: Santen
November 20, 2006
- Meiji Seika Licenses Penem, Antithrombotic Agents to US Companies
November 20, 2006
- BUSINESS NEWS IN BRIEF
November 20, 2006
- Henry McKinnell Decorated with Grand Cordon: Pfizer Japan
November 20, 2006
- Information Disclosure Key to Better Industry Image in Japan
November 20, 2006
- 7th Kitasato University-Harvard School of Public Health Symposium -1-
November 20, 2006
- 7th Kitasato University-Harvard School of Public Health Symposium -2-
November 20, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 20, 2006
- R&D NEWS IN BRIEF
November 20, 2006
- Takeda Seeking Acquisition Opportunities in Specific Fields
November 20, 2006
- NEW PRODUCTS
November 20, 2006
- Astellas to Embark on Asian Studies
November 20, 2006
- Medtronic Opens Training Center
November 20, 2006
- Daiichi Sankyo: Olmetec/Benicar Drove Increase in Sales
November 20, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…